DrugPatentWatch Database Preview
Investigational Drug Information for INC280
Email this page to a colleague
What is the drug development status for INC280?
INC280 is an investigational drug.
There have been 36 clinical trials for INC280.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 25th 2020.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Carcinoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, Array BioPharma, and National Cancer Institute (NCI).
There are one hundred and one US patents protecting this investigational drug and one international patent.
Summary for INC280
| US Patents | 101 |
| International Patents | 1,131 |
| US Patent Applications | 429 |
| WIPO Patent Applications | 319 |
| Japanese Patent Applications | 133 |
| Clinical Trial Progress | Phase 2 (2020-09-25) |
| Vendors | 71 |
Recent Clinical Trials for INC280
| Title | Sponsor | Phase |
|---|---|---|
| Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC | Novartis Pharmaceuticals | Phase 2 |
| Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy | Novartis Pharmaceuticals | Phase 3 |
| Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | Novartis Pharmaceuticals | Phase 2 |
Clinical Trial Summary for INC280
Top disease conditions for INC280
Top clinical trial sponsors for INC280
US Patents for INC280
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| INC280 | ⤷ Sign up for a Free Trial | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | Signal Pharmaceuticals, LLC (San Diego, CA) | ⤷ Sign up for a Free Trial |
| INC280 | ⤷ Sign up for a Free Trial | Methods of treating vestibular schwannoma and reducing hearing or neurite loss caused by vestibular schwannoma | Massachusetts Eye and Ear Infirmary (Boston, MA) | ⤷ Sign up for a Free Trial |
| INC280 | ⤷ Sign up for a Free Trial | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | ⤷ Sign up for a Free Trial |
| INC280 | ⤷ Sign up for a Free Trial | Methods of treating pediatric cancers | Loxo Oncology, Inc. (Stamford, CT) | ⤷ Sign up for a Free Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for INC280
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| INC280 | European Patent Office | EP3131552 | 2034-04-16 | ⤷ Sign up for a Free Trial |
| INC280 | Spain | ES2823756 | 2034-04-16 | ⤷ Sign up for a Free Trial |
| INC280 | Japan | JP2017514806 | 2034-04-16 | ⤷ Sign up for a Free Trial |
| INC280 | Japan | JP2019070012 | 2034-04-16 | ⤷ Sign up for a Free Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
